Credits Available: 4.5 AMA PRA Category 1 Credit™ & 4.5 MOC points, 4.5 ACPE

Description: Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries, with an age-adjusted incidence of 4.6 per 100,000 individuals per year. As small lymphocytic lymphoma (SLL) refers to the same malignant process with primary nodal involvement rather than blood, these are generally managed as a single condition (CLL/SLL). The selection of therapies for patients with relapsed/refractory CLL/SLL requires consideration of several factors including previous therapies, disease characteristics, and patient-specific factors such as co-morbidities and concurrent medications. Given the recency of new research into these targeted treatments and new approvals, clinicians lack background knowledge of the most current evidence and guideline recommendations in the treatment of CLL/SLL. Even within national guidelines, specific recommendations for initial treatment choice and sequencing are not directed. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL).

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Hematology, Hematology/Oncology, Oncology

Bhavesh Shah

boston medical center health system
Associate Chief Pharmacy Officer Hematology/Oncology and Specialty Pharmacy

Bhavesh Shah, R.Ph, BCOP, earned a bachelor of science in pharmacy degree at Massachusetts College of Pharmacy and Health Sciences subsequent to receiving a biochemistry degree from Loyola University Chicago. A board-certified oncology pharmacist, Mr. Shah is presently the Senior Director of Specialty and Hematology/Oncology Pharmacy Services at Boston Medical Center Health System. In this role, he is responsible for the clinical and operational efficiency of the cancer center, specialty pharmacy, and various ambulatory specialty areas. Mr. Shah also oversees clinical support for specialty programs for a managed care medicaid plan with over 400,000 lives
He has research experience is in COVID-19, biosimilars, cancer-related anorexia and cachexia syndrome, prevention of chemotherapy-induced nausea and vomiting, treatment of iron deficiency anemia, lung cancer digital adherence technology, immune thrombocytopenia purpura, and inflammatory bowel disease. He is a reviewer for the Annals of Pharmacotherapy, American Journal of Health System Pharmacy and has written articles in the Journal of Oncology Pharmacy Practice, Supportive Care in Cancer, and Biology of Blood and Marrow Transplantation. Mr. Shah has presented both nationally and internationally on biosimilars, specialty pharmacy arena, 340b, and the field of hematology/oncology pharmacy.